Moderna
was rising Monday after an analyst at Jefferies upgraded the inventory citing confidence within the vaccine maker’s progress alternatives that aren’t associated to the Covid-19 vaccine.
Jefferies analyst Michael Yee upgraded shares of Moderna (ticker: MRNA) to Buy from Hold and elevated his 12-month worth goal on the inventory to $275 from $170. For Moderna, Yee mentioned he sees a “significant new pipeline story and catalysts ahead.”
www.barrons.com
